Arbutus Biopharma Logo
Assembly Biosciences and Arbutus Biopharma Initiate Phase 2 Clinical Trial of Triple Combination Therapy for the Treatment of Chronic Hepatitis B Virus Trial will evaluate Assembly’s core inhibitor candidate, vebicorvir, with Arbutus’ RNAi therapeutic candidate, AB-729, and standard-of-care NrtI therapy SOUTH SAN FRANCISCO, Calif., and WARMINSTER,...
Arbutus Biopharma Logo
Arbutus to Report Fourth Quarter and Year End 2020 Financial Results and Provide Corporate Update
February 22, 2021 08:00 ET | Arbutus Biopharma Corporation
WARMINSTER, Pa., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with...
Arbutus Biopharma Logo
Arbutus Announces 2021 Corporate Objectives and Provides Financial Update
January 25, 2021 07:30 ET | Arbutus Biopharma Corporation
2021 objectives leverage positive momentum in Arbutus’ Hepatitis B research and development programs WARMINSTER, Pa., Jan. 25, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS),...
Arbutus Biopharma Logo
Arbutus to Participate in Virtual Fireside Chat at H.C. Wainwright BioConnect 2021 Conference
January 04, 2021 08:00 ET | Arbutus Biopharma Corporation
WARMINSTER, Pa., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with...
Arbutus Biopharma Logo
Arbutus Announces Robust HBsAg Decline Data with AB-729 Dosed at 60 mg Every 8 Weeks in Chronic Hepatitis B Subjects
December 10, 2020 07:30 ET | Arbutus Biopharma Corporation
Repeat dosing of 60 mg AB-729 every 8 weeks resulted in mean HBsAg declines of –1.37 log10 (N=6) comparable to AB-729 dosed every 4 weeks (–1.44 log10, N=7, p<0.7) AB-729 remains generally safe...
Arbutus Biopharma Logo
Arbutus Announces Additional Robust HBsAg Decline Data with AB-729 in Chronic Hepatitis B Subjects
November 16, 2020 07:00 ET | Arbutus Biopharma Corporation
Data released today expands on November 15, 2020 AASLD presentation Repeat dosing of 60 mg AB-729 every 4 weeks resulted in robust and continuous mean declines in HBsAg decline at week 20 (-1.71...
Arbutus Biopharma Logo
Arbutus Announces Presentation of Phase 1a/1b Clinical Trial Results for AB-729 in Chronic Hepatitis B Subjects at The Liver Meeting Digital Experience™, The American Association for the Study of Liver Diseases Meeting
November 15, 2020 14:40 ET | Arbutus Biopharma Corporation
Across all single-dose cohorts, mean HBsAg concentrations continuously declined up to week 12 before reaching a plateau, suggesting dosing of AB-729 less frequently than every 4 weeks may be warranted...
Arbutus Biopharma Logo
Arbutus to Present at Jefferies Virtual London Healthcare Conference
November 10, 2020 08:00 ET | Arbutus Biopharma Corporation
WARMINSTER, Penn., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with...
Arbutus Biopharma Logo
Arbutus Reports Third Quarter 2020 Financial Results and Provides Corporate Update
November 05, 2020 07:30 ET | Arbutus Biopharma Corporation
Results from an ongoing Phase 1a/1b clinical trial for Arbutus’ AB-729, a subcutaneously delivered RNAi agent, in subjects with chronic hepatitis B virus (HBV) infection, to be presented at the...
Arbutus Biopharma Logo
Arbutus to Report Third Quarter 2020 Financial Results and Provide Corporate Update
October 29, 2020 08:00 ET | Arbutus Biopharma Corporation
WARMINSTER, Pa., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company primarily focused on developing a cure for people with...